American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: http://www.sciepub.com/journal/ajmcr Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Medical Case Reports. 2017, 5(12), 298-300
DOI: 10.12691/ajmcr-5-12-4
Open AccessCase Report

Acute Kidney Injury Associated with Sofosbuvir-Simeprevir in a Patient with Chronic Hepatitis C Virus Infection and HIV Infection: A Case Report

Yasin H1, , Mathews M1, Suh J1 and Finkel D1

1St Joseph regional medical center

Pub. Date: January 15, 2018

Cite this paper:
Yasin H, Mathews M, Suh J and Finkel D. Acute Kidney Injury Associated with Sofosbuvir-Simeprevir in a Patient with Chronic Hepatitis C Virus Infection and HIV Infection: A Case Report. American Journal of Medical Case Reports. 2017; 5(12):298-300. doi: 10.12691/ajmcr-5-12-4

Abstract

Sofosbuvir and Simeprevir are new antiviral agents that have been used to treat chronic hepatitis C virus infection in the recent years with excellent virological response. Both agents are considered to have a safe renal profile. We present a 57-year-old male patient with chronic hepatitis c virus infection who developed acute kidney injury requiring hemodialysis after 7 weeks from beginning of Sofosbuvir and Simeprevir regimen. There was no renal side effects reported in clinical trials of both agents and There was only one reported case of kidney injury in patient taking Sofosbuvir in combination with Ledipasvir.

Keywords:
Sofosbuvir Simeprevir Hepatitis C

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Lawitz, Eric, Gary Matusow, Edwin DeJesus, Eric M. Yoshida, Franco Felizarta, Reem Ghalib, Eliot Godofsky et al. “Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST‐2).” Hepatology (2015).
 
[2]  Chopp, S., Vanderwall, R., HUIT, A., & Klepser, M. (2015). Simeprevir and sofosbuvir for treatment of hepatitis C infection. American Journal of Health-System Pharmacy, 72(17).
 
[3]  Bunchorntavakul, C., & Tanwandee, T. (2015). Treatment of Chronic Hepatitis C in Special Populations. Gastroenterology Clinics of North America, 44(4), 883-900.
 
[4]  Saab, S., Greenberg, A., Li, E., Bau, S. N., Durazo, F., El‐Kabany, M., ... & Busuttil, R. W. (2015). Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver International, 35(11), 2442-2447.
 
[5]  Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., ... & Rustgi, V. (2014). Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New England Journal of Medicine, 370(20), 1879-1888.
 
[6]  Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales Jr, F. L., ... & Craxi, A. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347(13), 975-982.
 
[7]  Aqel, B. A., Pungpapong, S., Leise, M., Werner, K., Chervenak, A. E., Watt, K. D., ... & Vargas, H. E. (2015). Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology, 62(4), 1004-1012.
 
[8]  Butt, A. A., Yan, P., Shaikh, O. S., Chung, R. T., & Sherman, K. E. (2015). Sofosbuvir‐based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver International.
 
[9]  Wanchoo, R., Thakkar, J., Schwartz, D., & Jhaveri, K. D. (2016). Harvoni (Ledipasvir With Sofosbuvir)-Induced Renal Injury. The American journal of gastroenterology, 111(1), 148.
 
[10]  Maruyama, A., Partovi, N., Yoshida, E. M., Erb, S. R., Azalgara, V. M., & Hussaini, T. (2015). A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease. Nephrology Dialysis Transplantation, gfv361.
 
[11]  Burgess, S., Partovi, N., Yoshida, E. M., Erb, S. R., Azalgara, V. M., & Hussaini, T. (2015). A Review of Drug Interactions With Direct-Acting Antivirals for Hepatitis C Implications for HIV and Transplant Patients. Annals of Pharmacotherapy, 1060028015576180.
 
[12]  Sofosbuvir full prescribing information. (n.d.). Retrieved from http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf
 
[13]  simeprevir full prescribing information. (n.d.). Retrieved from http://www.olysio.com/shared/product/olysio/prescribing-information.pdf.
 
[14]  Fontaine, Hélène, et al. “Bradyarrhythmias Associated with Sofosbuvir Treatment.” N Engl J Med 373.19 (2015): 1886-8.
 
[15]  Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., ... & Schwartz, H. (2014). Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine, 370(3), 211-221.
 
[16]  Jacobson, Ira M., et al. “SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study.” Hepatology 58.Suppl 1 (2013): 1379A.
 
[17]  Lawitz, E., Poordad, F. F., Pang, P. S., Hyland, R. H., Ding, X., Mo, H., ... & Membreno, F. E. (2014). Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. The Lancet, 383(9916), 515-523.
 
[18]  Osinusi, A., Meissner, E. G., Lee, Y. J., Bon, D., Heytens, L., Nelson, A., ... & Herrmann, E. (2013). Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.Jama, 310(8), 804-811.
 
[19]  Nazario, H. E., Ndungu, M., & Modi, A. A. (2015). Sofosbuvir and simeprevir in hepatitis C genotype 1‐patients with end‐stage renal disease on haemodialysis or GFR< 30 ml/min. Liver International.
 
[20]  Hundemer, G. L., Sise, M. E., Wisocky, J., Ufere, N., Friedman, L. S., Corey, K. E., & Chung, R. T. (2015). Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infectious Diseases, 47(12), 924-929.
 
[21]  Saxena, V., Koraishy, F. M., Sise, M. E., Lim, J. K., Schmidt, M., Chung, R. T., ... & Terrault, N. A. (2016). Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function. Liver International.
 
[22]  Rokx, C., Alshangi, H., Verbon, A., Zietse, R., Hoorn, E. J., & Rijnders, B. J. (2015). Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.Journal of Infectious Diseases, jiv466.
 
[23]  Jin, S., Kim, M. H., Park, J. H., Jung, H. J., Lee, H. J., Kim, S. W., ... & Chang, H. H. (2015). The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/Emtricitabine-containing HAART Regimens. Infection & chemotherapy, 47(4), 239-246.